Better Therapeutics to Participate in Cowen 7th Annual FutureHealth Conference

SAN FRANCISCO--()--Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced that Kevin Appelbaum, Co-Founder and CEO, will participate in the Commercializing Prescription Digital Therapeutics panel at the Cowen 7th Annual FutureHealth Conference on Thursday, June 23, 2022 at 12:40 p.m. ET.

The live panel will be available to registered participants in the conference. To listen to the live panel, please contact your Cowen representative.

About Better Therapeutics

Better Therapeutics is a prescription digital therapeutics (PDT) company developing a novel form of cognitive behavioral therapy to address the root causes of cardiometabolic diseases. The company has developed a proprietary platform for the development of FDA-regulated, software-based solutions for type 2 diabetes, heart disease and other conditions. The cognitive behavioral therapy delivered by Better Therapeutics’ PDT is designed to enable changes in neural pathways of the brain so lasting changes in behavior become possible. Addressing the underlying causes of these diseases has the potential to dramatically improve patient health while lowering healthcare costs. Better Therapeutics clinically validated mobile applications are intended to be prescribed by physicians and reimbursed like traditional medicines.

For more information visit: bettertx.com

Contacts

Investor Relations:
Mark Heinen
IR@bettertx.com

Media:
Ryan McKenna at Real Chemistry
rmckenna@realchemistry.com

Contacts

Investor Relations:
Mark Heinen
IR@bettertx.com

Media:
Ryan McKenna at Real Chemistry
rmckenna@realchemistry.com